Novo Nordisk A/S (NOVOBN.MX)
| Previous close | 2,150.39 |
| Open | 0.00 |
| Bid | 0.00 x N/A |
| Ask | 0.00 x N/A |
| Day's range | 0.00 - 0.00 |
| 52-week range | |
| Volume | |
| Avg. volume | 2,734 |
| Market cap | N/A |
| Beta (5Y monthly) | 0.19 |
| PE ratio (TTM) | 34.63 |
| EPS (TTM) | 62.09 |
| Earnings date | 07 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
Investor's Business DailyIs Eli Lilly Stock A Buy Or A Sell With Key Alzheimer's Meeting Looming?
Eli Lilly stock broke out and then retreated into sell-zone territory. With shares on the rise again, is LLY stock a buy?
GlobeNewswireNovo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
Bagsværd, Denmark, 15 May 2024 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse. The company’s board members, executives and their associated persons have reported the transactions to Novo Nordisk and have given Novo Nordisk power of attorney on their behalf to publish trading in Novo Nordisk shares by the
- GlobeNewswire
Novo Nordisk A/S: Once-weekly and once-monthly Mim8 demonstrate superior reduction of treated bleeding episodes compared to on-demand and prior prophylaxis treatment in people with haemophilia A in the Frontier 2 trial
Bagsværd, Denmark, 13 May 2024 – Novo Nordisk today announced the headline results from the FRONTIER 2 trial, a pivotal phase 3a, 26-week open-label, randomised, controlled, multi-arm trial in 254 people. The trial investigated the efficacy and safety of once-weekly and once-monthly subcutaneous Mim8 versus no prophylaxis and versus prior coagulation factor prophylaxis treatment in people aged 12 years or older with haemophilia A with or without inhibitors. The trial achieved its co-primary endp
